FDA considers relaxing electroshock device regulation

The FDA is weighing whether to downgrade the risk classification of electroshock devices used to treat major depression and other diseases, thus allowing devicemakers to introduce new products without costly clinical tests. Advocates say the treatment is much safer than it's been in the past, while opponents worry that the procedure causes memory loss and brain damage. An FDA advisory panel will review the proposal this week, according to the New York TimesReport

Suggested Articles

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.

Emmecell aims to make corneal transplant surgery, which can take up to a year to heal from and fails up to 20% of the time, a relic of the past.

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.